News & Updates
Filter by Specialty:
Forgoing radiotherapy possible for select postmenopausal women with early breast cancer
For postmenopausal women with genomically defined low-risk stage I breast cancer who have been initiated on endocrine therapy immediately after breast-conserving surgery, the risk of recurrence is low despite the omission of radiation therapy, as shown in the IDEA* trial.
Forgoing radiotherapy possible for select postmenopausal women with early breast cancer
10 Jan 2024Add-on carfilzomib yields benefits in transplant-ineligible NDMM patients
The addition of carfilzomib to lenalidomide and dexamethasone (KRd) improved outcomes in individuals with newly diagnosed fit or intermediate-fit multiple myeloma who are transplant ineligible (NTE NDMM) as opposed to Rd only in the phase III EMN20 trial.
Add-on carfilzomib yields benefits in transplant-ineligible NDMM patients
10 Jan 2024Capivasertib-fulvestrant improves life quality in advanced breast cancer
The addition of capivasertib (C) to fulvestrant (F) results in better health-related quality of life (HRQoL), except for diarrhoea, in patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer when compared to placebo plus F, according to the phase III CAPItello-291 study presented at SABCS 2023.